Novacyt (LON:NCYT) Releases Quarterly Earnings Results

Novacyt (LON:NCYT) posted its earnings results on Thursday. The company reported GBX (33) earnings per share for the quarter, Digital Look Earnings reports. Novacyt had a negative return on equity of 62.56% and a negative net margin of 125.04%.The firm had revenue of GBX 2,003 million for the quarter.

Novacyt Trading Down 7.1%

LON NCYT opened at GBX 27.44 on Friday. The stock has a market cap of £19.89 million, a P/E ratio of -0.64 and a beta of 1.06. Novacyt has a fifty-two week low of GBX 27 and a fifty-two week high of GBX 54. The stock has a 50 day simple moving average of GBX 32.93 and a two-hundred day simple moving average of GBX 35.72. The company has a debt-to-equity ratio of 26.81, a quick ratio of 4.46 and a current ratio of 5.03.

About Novacyt

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.